Novartis (NVS) Tops Q3 EPS by 2c; Offers Guidance

Novartis (NYSE: NVS) reported Q3 EPS of $1.58, $0.02 better than the analyst estimate of $1.56. Revenue for the quarter came in at $12.54 billion versus the consensus estimate of $12.92 billion.

GUIDANCE:

2022 Group guidance confirmed at mid single digit sales and core operating income growth. Sandoz guidance revised upwards, with sales expected to grow low to mid single digit (from low single digit) and core operating income expected to grow low single digit (from broadly in line).

For earnings history and earnings-related data on Novartis (NVS) click here.

You May Also Be Interested In

• Procter & Gamble (PG) revenue falls short of expectations, raises full-year earnings guidance
• Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
• Schlumberger Ltd. (SLB) Reports In-Line Q1 EPS